Antifungal Prophylaxis in Liver Transplant Recipients Adult Inpatient Clinical Practice Guideline
|
|
- Anis McCoy
- 5 years ago
- Views:
Transcription
1 Antifungal Prophylaxis in Liver Transplant Recipients Adult Inpatient Clinical Practice Guideline Table of Contents EXECUTIVE SUMMARY... 3 SCOPE... 3 METHODOLOGY... 4 DEFINITIONS... 5 INTRODUCTION... 5 RECOMMENDATIONS... 5 UW HEALTH IMPLEMENTATION... 6 REFERENCES... 7 CPG Contact for Changes: Philip Trapskin, PharmD, BCPS; Drug Policy Program Manager Phone Number: Address: PTrapskin@uwhealth.org CPG Contact for Content: Lucas Schulz, PharmD, BCPS AQ-ID Phone Number: Address: LSchulz2@uwhealth.org 1 Contact: Lee Vermeulen, Last Revised: 07/2016
2 Guideline Authors: Sara Koth, PharmD; Lucas Schulz, PharmD, BCPS AQ-ID; Margaret Jorgenson, PharmD, BCPS; Dave Hager, PharmD, BCPS Coordinating Team Members Joshua Vanderloo, PharmD, Drug Policy Program Lucas Schulz, PharmD, BCPS AQ-ID Review Individuals/Bodies: David Andes, MD Luis Fernandez, MD Barry Fox, MD Alex Lepak, MD Jeannina Smith, MD Jaime Myers, Liver Transplant Manager Committee Approvals/Dates: Antimicrobial Use Subcommittee, July 2015; November 2015, July 2016 UWHealth P&T Committee, September 2015; November 2015, July 2016 Release Date: September 2015; Minor revisions: November 2015, July 2016 Next Review Date: September Contact: Lee Vermeulen, Last Revised: 07/2016
3 Executive Summary Guideline Overview This document is intended to guide clinicians in the screening of liver transplant recipients to determine their risk for invasive fungal infections and initiating antifungal prophylaxis when appropriate. Key Practice Recommendations 1. Liver transplant patients should be evaluated for risk of postoperative invasive fungal infection. (Class I, Level C) 2. Liver transplant patients at high risk of invasive fungal infection should receive antifungal prophylaxis with either fluconazole or micafungin. (Fluconazole Class I, Level B; Micafungin Class IIb, Level C) 3. Antifungal selection based on patient and microbiological factors may be reasonable. (Class IIb, Level C) Companion Documents Liver Transplant Antifungal Prophylaxis Delegation Protocol [123] Pertinent UW Health Policies & Procedures None Scope Disease/Condition: Patients undergoing liver transplantation. Clinical Specialty: Transplant, Pharmacy Intended Users: Transplant surgeons, physicians, physician assistants, advanced practice nurse practitioners, pharmacists CPG Objectives: To guide clinicians in identifying liver transplant recipients at high risk for invasive fungal infections based on recipient risk factors. Selection and initiation of antifungal prophylaxis when appropriate based on these risk factors. Target Population: Adult patients who have received a liver transplant Interventions and Practices Considered: This guideline provides recommendations for the identification of liver transplant recipients at high risk of developing an invasive fungal infection. It also provides recommendations on the use, dosing, and duration of antifungal prophylaxis in patients at high risk for developing an invasive fungal infection after transplant. Major Outcomes Considered: Rates of invasive fungal infections after transplant Rates of adverse effects with antifungal medications Antifungal resistance rates 3 Copyright 201 University of Wisconsin Hospitals and Clinics Authority Contact: Lee Vermeulen, Last Revised: 07/2016
4 Guideline Metrics: Identification of high-risk liver transplant recipients Initiation of antifungal prophylaxis in high-risk patients Incidence of invasive fungal infections after transplant Methodology 1. PUBMED was searched using the terms antifungal prophylaxis AND liver transplant. References from identified articles were further evaluated. Internal expert opinion was also incorporated into guideline development in cases of a lack of evidence or conflicting evidence. 2. A modified Grading of Recommendations Assessment, Development, and Evaluation (GRADE) developed by the American Heart Association and American College of Cardiology Foundation has been used to assess the Quality and Strength of the Evidence in this Clinical Practice Guideline (Figure1). 1 4 Contact: Lee Vermeulen, Last Revised: 07/2016
5 Definitions IFI: Invasive fungal infection Introduction Invasive fungal infections (IFIs) have been associated with increased mortality, length of hospital stay and overall cost. 2,3 Liver transplant recipients are at high risk for IFIs because of the immunosuppression required and risk factors associated with surgery. 3,4 In June 2013, the United Network of Organ Sharing (UNOS) instituted the Share 35 Regional Policy, which shares organs not only with local but regional candidates with MELD scores of 35 and higher. With the advent of this policy, UWHC providers have been transplanting patients with higher MELD scores more frequently. Although these patients generally have more risk factors for IFIs, IFI prophylaxis has been non-standardized. The aim of this guideline is to standardize the process for identifying high-risk patients and prescribing appropriate antifungal prophylaxis with the goals of reducing the incidence of IFIs after transplant and minimizing the use and consequences of long-term antifungal medications used to treat IFIs. Recommendations 1. Screening for liver transplant recipients at high risk for invasive fungal infections 1.1. It is recommended that high-risk patients be defined as those with any of the following risk factors: (Class I, Level B) Operation time greater than 10 hours in duration 5-9 Any repeat operation within 30 days of transplant 5,7,9-17 Retransplantation 5-17 Dialysis requirement prior to transplant 5-7,9,11-14 High intra-operative transfusion requirement during transplant surgery 5-14 o Greater than or equal to 40 units of cellular blood products (platelets, prbcs, plasma, cryoprecipitate) History of choledocho-jejunostomy 5-8,11-16 Candida colonization in the peri-operative period 5-9,11-15 o One or more cultures positive for Candida within one month of prior to transplant o Active treatment for Candida infection at the time of transplant Physiologic MELD equal to or greater than 35 (Class IIb, Level C) Hospital admission seven days or longer prior to liver transplant (Class IIb, Level C) ICU admission within seven prior to transplant (Class IIb, Level C) 2. Ordering of prophylaxis for high-risk liver transplant recipients 2.1. All high-risk patients should receive antifungal prophylaxis post-transplant. (Class I, Level C) 2.2. Fluconazole at a dose of 400 mg by mouth daily is recommended prophylaxis. 5-7,9,12,14,15,18,19 (Class I, Level B) Fluconazole dose adjustment for renal dysfunction is not indicated due to low risk of toxicity and wide therapeutic index. (Class IIb, Level C) An alternative regimen is probably indicated for patients with prior isolation of a fluconazole-resistant Candida isolate. (Class IIb, Level C) An alternative regimen is probably indicated for patients who have received triazole treatment dosing (fluconazole 400 mg daily for at least seven days or equivalent) within the previous 90 days. (Class IIb, Level C) If micafungin is used for this indication, it should not be considered for outpatient antibiotic therapy (OPAT) if the patient has improved rapidly and is ready for discharge before fourteen days. 3,6,7,9,12,14-16,20,21 (Class III, Level C) 2.3. Fourteen days of prophylaxis duration of therapy may be reasonable. (Class IIb, Level C) Extension of antifungal prophylaxis beyond fourteen days may be considered if risk factors persist (e.g. ongoing biliary leak). (Class IIb, Level C) 5 Contact: Lee Vermeulen, Last Revised: 07/2016
6 If the patient is discharged from the transplant encounter prior to fourteen days of systemic prophylaxis, discontinuation of antifungal prophylaxis may be considered at discharge. (Class IIb, Level C) 2.4. While fluconazole resistance is rising in Candida species, the rate of fluconazole-resistant Candida albicans at UWHC is low (below 5%) Alternative to fluconazole 3.1. The risk of hepatic injury is low with fluconazole, with approximately 1% of fluconazole-treated patients experiencing a significant elevation in serum transaminase levels in clinical trials. Hepatic metabolism is generally not clinically significantly altered until the patient has a Child Pugh Score of C. In a patient with a Child Pugh Score of C, micafungin can be recommended. 9,11,14,20,21 (Class IIa, Level B) In the case of a fluconazole allergy or intolerance, micafungin 100 mg IV daily is probably recommended. 9,14,20 (Class IIa, Level B) Liposomal amphotericin B has been studied for the prevention of IFIs after liver transplantation. 22 Given alternatives with comparable outcomes and the higher risk of nephrotoxicity with liposomal amphotericin B, this agent is not currently preferred for routine use as antifungal prophylaxis in liver transplant recipients. 17 (Class III, Level B). UW Health Implementation Potential Benefits: The primary benefit of implementation of this guideline is the standardization of screening for patients at high risk for developing invasive fungal infections after liver transplant and ensuring that they receive antifungal prophylaxis. Potential Harms: The risk of implementing this guideline and administering antifungal prophylaxis is an increase in side effects such as nausea, vomiting and headache as well as a need for close monitoring of drug interactions with immunosuppressive medications. Qualifying Statements There is a lack of consensus regarding various risk factors for IFIs in liver transplant recipients and various levels of evidence; therefore, these guidelines are based on current evidence and local expert opinion. The recommendations included in this guideline are subject to change with publication of additional evidence. Implementation Plan/Tools 1. Document will be housed on U-Connect on the Guideline webpage. 2. Education on this guideline will be distributed to liver transplant surgeons and clinical pharmacists through service line meetings 3. A pharmacist delegation protocol will be created 4. Reference links to the guideline will be added to fluconazole and micafungin medication records Disclaimer CPGs are described to assist clinicians by providing a framework for the evaluation and treatment of patients. This Clinical Practice Guideline outlines the preferred approach for most patients. It is not intended to replace a clinician s judgment or to establish a protocol for all patients. It is understood that some patients will not fit the clinical condition contemplated by a guideline and that a guideline will rarely establish the only appropriate approach to a problem. 6 Contact: Lee Vermeulen, Last Revised: 07/2016
7 References 1. Tricoci P, Allen JM, Kramer JM, Califf RM, Smith SC, Jr. Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA. Feb ;301(8): Menzin J, Meyers JL, Friedman M, et al. Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. Am J Health Syst Pharm. Oct ;66(19): Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. Mar ;48(5): Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. Apr ;50(8): Eschenauer GA, Kwak EJ, Humar A, et al. Targeted versus universal antifungal prophylaxis among liver transplant recipients. Am J Transplant. Jan 2015;15(1): Perrella A, Esposito C, Pisaniello D, et al. Role of liposomal amphotericin B prophylaxis after liver transplantation compared with fluconazole for high-risk patients. impact on infections and mortality within one year. Transplant Proc. Sep 2012;44(7): Silveira FP, Kusne S. Candida infections in solid organ transplantation. Am J Transplant. Mar 2013;13 Suppl 4: Trudeau RE, Bowman LJ, Wills AR, Crippin JS, Chapman WC, Anderson C. Once weekly fluconazole for antifungal prophylaxis post-liver transplantation. HPB (Oxford). Jul 2013;15(7): Winston DJ, Limaye AP, Pelletier S, et al. Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients. Am J Transplant. Dec 2014;14(12): Castroagudin JF, Ponton C, Bustamante M, et al. Prospective interventional study to evaluate the efficacy and safety of liposomal amphotericin B as prophylaxis of fungal infections in high-risk liver transplant recipients. Transplant Proc. Nov 2005;37(9): Fortun J, Martin-Davila P, Montejo M, et al. Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients. Transplantation. Feb ;87(3): Hadley S, Huckabee C, Pappas PG, et al. Outcomes of antifungal prophylaxis in high-risk liver transplant recipients. Transpl Infect Dis. Feb 2009;11(1): Pappas PG, Andes D, Schuster M, et al. Invasive fungal infections in low-risk liver transplant recipients: a multi-center prospective observational study. Am J Transplant. Feb 2006;6(2): Saliba F, Pascher A, Cointault O, et al. Randomized trial of micafungin for the prevention of invasive fungal infection in high-risk liver transplant recipients. Clin Infect Dis. Apr ;60(7): Saliba F, Delvart V, Ichai P, et al. Fungal infections after liver transplantation: outcomes and risk factors revisited in the MELD era. Clin Transplant. Jul-Aug 2013;27(4):E San-Juan R, Aguado JM, Lumbreras C, et al. Universal prophylaxis with fluconazole for the prevention of early invasive fungal infection in low-risk liver transplant recipients. Transplantation. Aug ;92(3): Sun HY, Cacciarelli TV, Singh N. Micafungin versus amphotericin B lipid complex for the prevention of invasive fungal infections in high-risk liver transplant recipients. Transplantation. Sep 2013;96(6): Winston DJ, Busuttil RW. Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. Transplantation. Sep ;74(5): Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. Nov ;131(10): Evans JD, Morris PJ, Knight SR. Antifungal prophylaxis in liver transplantation: a systematic review and network meta-analysis. Am J Transplant. Dec 2014;14(12): DIFLUCAN (fluconazole) [package insert]. New York, New York; Pfizer; Revised March Tollemar J, Hockerstedt K, Ericzon BG, Jalanko H, Ringden O. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study. Transplantation. Jan ;59(1): Contact: Lee Vermeulen, Last Revised: 07/2016
Invasive Fungal Infections in Solid Organ Transplant Recipients
Outlines Epidemiology Candidiasis Aspergillosis Invasive Fungal Infections in Solid Organ Transplant Recipients Hsin-Yun Sun, M.D. Division of Infectious Diseases Department of Internal Medicine National
More informationContinuous Renal Replacement Therapy Based Dose Adjustments - Adult - Inpatient Clinical Practice Guideline
Continuous Renal Replacement Therapy Based Dose Adjustments - Adult - Inpatient Clinical Practice Guideline Note: Active Table of Contents Click to follow link Table of Contents EXECUTIVE SUMMARY... 3
More informationSolid organ transplant patients
M.6 Meet-the-expert sessions Solid organ transplant patients Martin Iversen, Denmark José M. Aguado, Spain Copenhagen, Sunday 13 October 2013 Conflict of interest disclosure In the past 5 years, J.M.A.
More informationItraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients D. J. Winston
REVIEW Itraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients D. J. Winston Division of Hematology-Oncology, Department of Medicine, UCLA Medical Center, Los
More informationCandiduria in ICU : when and how to treat? Dr. Debashis Dhar Dept of Critical Care and Emergency Medicine Sir Ganga Ram Hospital
Candiduria in ICU : when and how to treat? Dr. Debashis Dhar Dept of Critical Care and Emergency Medicine Sir Ganga Ram Hospital Introduction Nosocomial bacteriuria or candiduria develops in up to 25%
More informationTABLE 1a. Risk Factors for IFI for all fungal pathogens
LIVER TRANSPLANTATION 16:797-805, 2010 ERRATUM In Liver Transplantation volume 15, number 8 (August 2009), pp. 842-858, Eschenauer, Lam, and Carver, the tables should be revised as the following: DOI 10.1002/lt.22097
More informationReducing COPD Exacerbation Readmissions in a Community-Based Teaching Hospital
Reducing COPD Exacerbation Readmissions in a Community-Based Teaching Hospital Dawn Waddell, PharmD, BCPS Clinical Pharmacy Manager Lisa Kingdon, PharmD, BCPS Clinical Pharmacy Specialist Dawn Waddell
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Voriconazole Effective Date... 3/15/2018 Next Review Date... 3/15/2019 Coverage Policy Number... 4004 Table of Contents Coverage Policy... 1 General Background...
More informationMonitoring of Voriconazole levels at University Hospital. Jason Bowling, MD Rachel Rivera, MD
Monitoring of Voriconazole levels at University Hospital Jason Bowling, MD Rachel Rivera, MD Background Voriconazole is a second-generation azole antifungal drug. It is the preferred agent for treatment
More informationAntifungal Agents - Cresemba (isavuconazonium), Vfend. Prior Authorization Program Summary
Antifungal Agents - Cresemba (isavuconazonium), Noxafil (posaconazole), Vfend (voriconazole) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1,2,14 Drug FDA Indication(s) Dosing Cresemba
More informationEMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS
EMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS DR LOW CHIAN YONG MBBS, MRCP(UK), MMed(Int Med), FAMS Consultant, Dept of Infectious Diseases, SGH Introduction The incidence of invasive fungal
More informationSurgical Site Infection (SSI) Surveillance Update (with special reference to Colorectal Surgeries)
Surgical Site Infection (SSI) Surveillance Update (with special reference to Colorectal Surgeries) Where we started and where we re going Anjum Khan MBBS MSc CIC Infection Control Professional Department
More informationDisclosures. Learning Objectives 4/26/2017
Implementation of a quality improvement initiative to ensure the safe transition from prior-to-admission concentrated insulins to a formulary insulin regimen ERICA J. RHEIN, PHARMD PGY1 PHARMACY PRACTICE
More informationAntifungals and current treatment guidelines in pediatrics and neonatology
Dragana Janic Antifungals and current treatment guidelines in pediatrics and neonatology Dragana Janic. University Children`s Hospital, Belgrade, Serbia 10/10/17 Hotel Crowne Plaza, Belgrade, Serbia; www.dtfd.org
More informationFungal Infection in the ICU: Current Controversies
Fungal Infection in the ICU: Current Controversies Andrew F. Shorr, MD, MPH, FCCP, FACP Washington Hospital Center Georgetown University, Washington, DC Disclosures I have served as a consultant to, researcher/investigator
More informationanidulafungin 100mg powder and solvent for concentrate for solution for infusion (Ecalta ) No. (465/08) Pfizer Ltd
Scottish Medicines Consortium Re-Submission anidulafungin 100mg powder and solvent for concentrate for solution for infusion (Ecalta ) No. (465/08) Pfizer Ltd 10 October 2008 The Scottish Medicines Consortium
More information1. Introduction. Correspondence should be addressed to Ruey-Shyang Soong;
BioMed Research International Volume 2016, Article ID 6212503, 7 pages http://dx.doi.org/10.1155/2016/6212503 Research Article Effect of Prophylactic Antifungal Protocols on the Prognosis of Liver Transplantation:
More informationForm 2046 R3.0: Fungal Infection Pre-HSCT Date
Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Today's Date: - - Date of HSCT for which this form is being completed: - - HSCT type: (check all that apply) Autologous
More informationCaspofungin Versus Fluconazole as Prophylaxis of Invasive Fungal Infection in High-Risk Liver Transplantation Recipients: A Propensity Score Analysis
ORIGINAL ARTICLE Caspofungin Versus Fluconazole as Prophylaxis of Invasive Fungal Infection in High-Risk Liver Transplantation Recipients: A Propensity Score Analysis Jesus Fortun, 1 Alfonso Muriel, 2
More informationMonitoring Protocol for Clozapine-induced Myocarditis. Copyright 2017, CAMH
1 Monitoring Protocol for Clozapine-induced Myocarditis 1 Agenda Problem Identification / Identification Importance / Importance Baseline Workflow Baseline Workflow Baseline Data Baseline Data Objectives
More informationAntifungal Pharmacodynamics A Strategy to Optimize Efficacy
Antifungal Pharmacodynamics A Strategy to Optimize Efficacy David Andes, MD Associate Professor, Department of Medicine Division of Infectious Diseases Medical Microbiology and Immunology University of
More informationNorth Dakota Board of Pharmacy
North Dakota Board of Pharmacy Updates on Drug Abuse Trends, the PDMP and Medical Marijuana Mark J. Hardy, Pharm D Executive Director Disclosure Statement I have no conflict of interests to report Objectives
More informationWHAT IS THE ROLE OF EMPIRIC TREATMENT FOR SUSPECTED INVASIVE CANDIDIASIS IN NONNEUTROPENIC PATIENTS IN THE ICU?
WHAT IS THE ROLE OF EMPIRIC TREATMENT FOR SUSPECTED INVASIVE CANDIDIASIS IN NONNEUTROPENIC PATIENTS IN THE ICU? Empiric antifungal therapy should be considered in critically ill patients with risk factors
More information1. Pre-emptive therapy. colonization, colonization, pre-emptive therapy. , ICU colonization. colonization. 2, C. albicans
Jpn. J. Med. Mycol. Vol. 45, 217 221, 2004 ISSN 0916 4804,.,, colonization, pre-emptive therapy. 2, non-albicans Candida., fluconazole.,. Key words: postoperative infection, non-albicans Candida, pre-emptive
More informationNationwide survey of treatment for pediatric patients with invasive fungal infections in Japan
J Infect Chemother (2013) 19:946 950 DOI 10.1007/s10156-013-0624-7 ORIGINAL ARTICLE Nationwide survey of treatment for pediatric patients with invasive fungal infections in Japan Masaaki Mori Received:
More informationFungi GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Fungi Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA Chapter Editor Ziad A. Memish, MD, FRCPC, FACP Cover heading - Topic Outline Topic outline
More informationTo develop guidelines for the use of appropriate antibiotics for adult patients with CAP and guidance on IV to PO conversion.
Page 1 of 5 TITLE: COMMUNITY-ACQUIRED PNEUMONIA (CAP) EMPIRIC MANAGEMENT OF ADULT PATIENTS AND IV TO PO CONVERSION GUIDELINES: These guidelines serve to aid clinicians in the diagnostic work-up, assessment
More informationMicafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version February 2013
Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version 1.0 5 February 2013 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised
More informationCandida auris: an Emerging Hospital Infection
National Center for Emerging and Zoonotic Infectious Diseases Candida auris: an Emerging Hospital Infection Paige Armstrong MD MHS Epidemic Intelligence Service Officer Mycotic Diseases Branch Association
More informationFungal infections in ICU. Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia
Fungal infections in ICU Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia Epidemiology of invasive fungal infections - US +300% Martin GS, et al. N Engl J Med 2003;348:1546-1554
More informationPrevention of Fungal Infections: What is the Evidence for Antifungals?
Prevention of Fungal Infections: What is the Evidence for Antifungals? SHAHID HUSAIN, MD, MS Associate Professor of Medicine Director, Transplant Infectious Diseases University Health Network, University
More informationTitle: Author: Speciality / Division: Directorate:
Antifungal guidelines for CANDIDIASIS INFECTIONS (Adults) Proven infection: Targeted antifungal therapy should be prescribed for: o Positive cultures from a sterile site with clinical or radiological abnormality
More informationScottish Medicines Consortium
Scottish Medicines Consortium anidulafungin 100mg powder and solvent for concentrate for solution for infusion (Ecalta ) No. (465/08) Pfizer Ltd 09 May 2008 The Scottish Medicines Consortium (SMC) has
More informationAntifungals in Invasive Fungal Infections: Antifungals in neutropenic patients
BVIKM-SBIMC La Hulpe, 6 November 2008 Antifungals in Invasive Fungal Infections: Antifungals in neutropenic patients Johan Maertens, MD Acute Leukemia and SCT Unit University Hospital Gasthuisberg Catholic
More informationThink Globally: Strategies to Improve the Culture of Antibiotic Prescribing
Think Globally: Strategies to Improve the Culture of Antibiotic Prescribing October 11, 2017 Paul Lewis, PharmD, BCPS (AQ-ID) Johnson City Medical Center Johnson City, TN 1 Outline Introduction to stewardship
More informationMedication Policy Manual Policy No: Topic: Date of Origin: Committee Approval Date: Next Review Date: Effective Date: IMPORTANT REMINDER Description
Medication Policy Manual Policy No: dru301 Topic: Kynamro, mipomersen Date of Origin: May 16, 2013 Committee Approval Date: March 13, 2015 Next Review Date: March 2016 Effective Date: April 1, 2015 IMPORTANT
More informationAntimicrobial prophylaxis in liver transplant A multicenter survey endorsed by the European Liver and Intestine Transplant Association
Antimicrobial prophylaxis in liver transplant A multicenter survey endorsed by the European Liver and Intestine Transplant Association Els Vandecasteele, Jan De Waele, Dominique Vandijck, Stijn Blot, Dirk
More informationEvelina London Children s Hospital (ELCH)
Evelina London Children s Hospital (ELCH) Lead Consultant Jenny Handforth PID Pharmacist Faye Chappell Paediatric OPAT CNS Vacant Overview Paediatric OPAT in London Paediatric OPAT ELCH Children s Hospital
More informationWHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS?
WHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS? Assoc. Prof. Dr. Serkan SENER Acibadem University Medical School Department of Emergency Medicine, Istanbul Acibadem Ankara Hospital,
More informationThe EMPIRICUS trial the final nail in the coffin of empirical antifungal therapy in the intensive care unit?
Editorial The EMPIRICUS trial the final nail in the coffin of empirical antifungal therapy in the intensive care unit? Michael Osthoff 1,2, Nina Khanna 1,2, Martin Siegemund 3 1 Division of Infectious
More informationEast London Community Kidney Service
East London Community Kidney Service Sally Hull, Neil Ashman, Sec Hoong, Nicola Thomas, Helen Rainey April 2017 Haemodialysis/million population What is the Problem? Fast rising ESRD rates in East London
More informationThe Infection Control Doctor and Clostridium difficile infection. Dr David R Jenkins University Hospitals of Leicester NHS Trust, England
The Infection Control Doctor and Clostridium difficile infection Dr David R Jenkins University Hospitals of Leicester NHS Trust, England 250 200 150 100 50 0 Monthly cases of Clostridium difficile (UHL
More informationMicafungin, a new Echinocandin: Pediatric Development
Micafungin, a new Echinocandin: Pediatric Development Andreas H. Groll, M.D. Infectious Disease Research Program Center for Bone Marrow Transplantation and Department of Pediatric Hematology/Oncology University
More informationHow Can We Prevent Invasive Fungal Disease?
How Can We Prevent Invasive Fungal Disease? Chris Kibbler Professor of Medical Microbiology University College London And Royal Free Hospital, London, UK Invasive Aspergillosis 2 - Acquisition Preventive
More informationAn Update in the Management of Candidiasis
An Update in the Management of Candidiasis Daniel B. Chastain, Pharm.D., AAHIVP Infectious Diseases Pharmacy Specialist Phoebe Putney Memorial Hospital Adjunct Clinical Assistant Professor UGA College
More informationMALDI-TOF MS: Translating Microbiology Laboratory Alphabet Soup to Optimize Antibiotic Therapy
MALDI-TOF MS: Translating Microbiology Laboratory Alphabet Soup to Optimize Antibiotic Therapy September 8, 2017 Amy Carr, PharmD PGY-2 Infectious Diseases Pharmacy Resident Seton Healthcare Family amy.carr@ascension.org
More informationCurrent options of antifungal therapy in invasive candidiasis
Current options of antifungal therapy in invasive candidiasis Saloua Ladeb Bone Marrow Transplant Center Tunis HAMMAMET 24 th April 2012 DEFINITION One or more positive results on blood culture for Candida
More informationUpdate on Antifungal Stewardship
Update on Antifungal Stewardship Dr Jacqueline Sneddon, MRPharmS Scottish Antimicrobial Prescribing Group Antimicrobial Management Team event 7 th November 2017 ANTIFUNGAL STEERING GROUP CHAIR Prof Brian
More informationAli J. Olyaei, PharmD, BCPS. Director of Clinical Research Oregon Health & Sciences University
PATH Alliance Registry: Identification of Inappropriate Drug Dosing of Antifungal Agents in Patients with Chronic Kidney Disease Review of 6000 Patients with Fungal Infections Ali J. Olyaei, PharmD, BCPS
More informationI am against to TDM in critically ill patient
TDM I am against to TDM in critically ill patient TDM of antifungals: where are we? Dr. Rafael Zaragoza Antifungal therapy in ICU; prophylaxis, pre-emptive and targeted Conflicts of interest: Pfizer Astellas
More informationMeasure Information Form
Release Notes: Measure Information Form Version 2.5 **NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE** Measure Information Form Measure Set: Surgical Care Improvement Project (SCIP) Set Measure
More informationWhat have we learned about systemic antifungals currently available on the market?
2nd ECMM/CEMM Workshop Milano, September 25, 2010 What have we learned about systemic antifungals currently available on the market? Prof. Dr. Georg Maschmeyer Dept. of Hematology, Oncology & Palliative
More informationChallenges and controversies of Invasive fungal Infections
Challenges and controversies of Invasive fungal Infections Mona Al-Dabbagh, MD, MHSc Assistant Professor of Pediatrics, COM-KSAU-HS Consultant Pediatric Infectious Diseases and Transplant Infectious Diseases
More informationAmerican hospitals crawling towards Electronic Medical Records (EMR) and Computerized Physician Order Entry (CPOE)
Welcome! American hospitals crawling towards Electronic Medical Records (EMR) and Computerized Physician Order Entry (CPOE) Still
More informationOne Palliative Care Annual Report
One 203 Palliative Care Annual Report One In 202, ASCO released a provisional clinical opinion stating that concurrent palliative care should be considered early in the course of advanced or metastatic
More informationDAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health
More informationThe Hospital for Sick Children Technology Assessment at Sick Kids (TASK) EXECUTIVE SUMMARY
The Hospital for Sick Children Technology Assessment at Sick Kids (TASK) EXECUTIVE SUMMARY CASPOFUNGIN IN THE EMPIRIC TREATMENT OF FEBRILE NEUTROPENIA IN PEDIATRIC PATIENTS: A COMPARISON WITH CONVENTIONAL
More informationKato, M. Nagao, S. Nakano, T. Yunok. Citation Transplant infectious disease (
Title Itraconazole prophylaxis for invasi lung transplantation. Kato, K; Nagao, M; Nakano, S; Yunok Author(s) Yamamoto, M; Matsumura, Y; Ito, Y; Bando, T; Matsuda, Y; Matsubara, K; Citation Transplant
More informationOptimizing antifungal dosing regimens. Joseph Meletiadis, PhD, FECMM Assistant Professor of Microbiology
ATHENA 2017 International Conference November 28 30, 2017 Optimizing antifungal dosing regimens Joseph Meletiadis, PhD, FECMM Assistant Professor of Microbiology Clinical Microbiology Laboratory, «Attikon»
More informationAntifungal Prophylaxis in Liver Transplant Patients: A Systematic Review and Meta-analysis
LIVER TRANSPLANTATION 12:850-858, 2006 ORIGINAL ARTICLE Antifungal Prophylaxis in Liver Transplant Patients: A Systematic Review and Meta-analysis Mario Cruciani, 1 Carlo Mengoli, 2 Marina Malena, 1 Oliviero
More informationTop 5 papers in clinical mycology
Top 5 papers in clinical mycology Dirk Vogelaers Department of General Internal Medicine University Hospital Ghent Joint symposium BVIKM/BSIMC and SBMHA/BVMDM Influenza-associated aspergillosis in critically
More informationClostridium difficile (C. difficile) and Staphylococcus aureus bacteraemia (MRSA and MSSA) Bi-annual Report. Surveillance: Report:
Surveillance: Report: Clostridium difficile (C. difficile) and Staphylococcus aureus ( and ) Bi-annual Report Time period: 1 st April to 30 th September 2016 Health Board: Wales Content: Issued by: Pg
More informationWhen is failure failure?
When is failure failure? Bart-Jan Kullberg, M.D. Radboud University Nijmegen The Netherlands The ICU patient with candidemia!! Female, 39 years old!! Multiple abdominal surgeries for Crohn's disease!!
More informationRezafungin: A Novel Echinocandin. Taylor Sandison, MD MPH Chief Medical Officer ISHAM- Amsterdam July 2, 2018
: A Novel Echinocandin Taylor Sandison, MD MPH Chief Medical Officer ISHAM- Amsterdam July 2, 2018 Disclosures Dr. Sandison is an employee of and stockholder in Cidara Therapeutics. Cidara Pipeline Program
More informationDifficult to diagnose fungal infections: Non-fungaemic candidiasis
Difficult to diagnose fungal infections: Non-fungaemic candidiasis Director, Mycology Research Unit and XDR Pathogen Laboratory University of Pittsburgh Cornelius J. Clancy, M.D. Chief, Infectious Diseases
More informationAntifungal agents for preventing fungal infections in solid organ transplant recipients(review)
Cochrane Database of Systematic Reviews Antifungal agents for preventing fungal infections in solid organ transplant recipients(review) Playford EG, Webster AC, Craig JC, Sorrell TC Playford EG, Webster
More informationMcLean ebasis plus TM
McLean ebasis plus TM Sample Hospital (0000) Report For Qtr HBIPS Core Measures McLean Hospital 115 Mill Street Belmont, MA 02478 1 2012 Department of Mental Health Services Evaluation Tel: 617-855-3797
More information1 Guidelines for the Management of Candidaemia
1 Guidelines for the Management of Candidaemia LIVERPOOL CLINICAL LABORATORIES GUIDELINE FOR THE MANAGEMENT OF CANDIDAEMIA IN NON-NEUTROPENIC ADULT PATIENTS AND PROPHYLAXIS/PRE-EMPTIVE TREATMENT IN HIGH
More informationDose-dependent effects of tobramycin in an animal model of Pseudomonas sinusitis Am J Rhino Jul-Aug; 21(4):423-7
AMINOGLYCOSIDES Dose-dependent effects of tobramycin in an animal model of Pseudomonas sinusitis Am J Rhino. 2007 Jul-Aug; 21(4):423-7 http://www.ncbi.nlm.nih.gov/pubmed/17882910 Evaluation of the in-vivo
More informationCare Guideline DRAFT for review cycle 08/02/17 CARE OF THE ADULT PNEUMONIA PATIENT
Care Guideline DRAFT for review cycle 08/02/17 CARE OF THE ADULT PNEUMONIA PATIENT Target Audience: All MHS employed providers within Primary Care, Urgent Care, and In-Hospital Care. The secondary audience
More informationGYNAZOLE 1 (butoconazole nitrate) vaginal cream 2%
GYNAZOLE 1 (butoconazole nitrate) vaginal cream 2% Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan.
More informationImplementation of an Interprofessional Team to Prevent Inpatient Hypoglycemic Events. September 13, 2016
Implementation of an Interprofessional Team to Prevent Inpatient Hypoglycemic Events September 13, 2016 St Joseph s Health Fast Facts Founded 1869 by Sisters of St. Francis Patient Volumes (2014) Inpatient
More informationShannon Carty, PGY-2 ICCR IRB Project Proposal April 9, 2008
Shannon Carty, PGY-2 ICCR IRB Project Proposal April 9, 2008 Study Title: Observational Study to Determine the Effect of an Emergency Department Adult Oncology Stat Antibiotic Protocol on Clinical Outcomes
More informationCARE OF THE ADULT PNEUMONIA PATIENT
Care Guideline CARE OF THE ADULT PNEUMONIA PATIENT Target Audience: The target audience for this Care Guideline is all MultiCare providers and staff, including those associated with our clinically integrated
More informationInternational Journal of Infectious Diseases
International Journal of Infectious Diseases 15 (2011) e298 e304 Contents lists available at ScienceDirect International Journal of Infectious Diseases journal homepage: www.elsevier.com/locate/ijid Review
More informationReducing Readmissions and Improving Outcomes at OhioHealth Mansfield Hospital:
Reducing Readmissions and Improving Outcomes at OhioHealth Mansfield Hospital: Eugenio H. Zabaleta, Ph.D. Clinical Chemist OhioHealth Mansfield Hospital Reducing Readmissions and Improving Outcomes at
More informationSurgical antibiotic prophylaxis at Epworth Healthcare
Surgical antibiotic prophylaxis at Epworth Healthcare Dr Joseph Doyle MPH PhD FRACP Infectious Diseases Physician Epworth, Alfred Health & Melbourne Health Senior Lecturer & NHMRC Clinical Research Fellow,
More informationFurther Evolution of the ACC/AHA Clinical Practice Guideline Recommendation Classification System
Further Evolution of the ACC/AHA Clinical Practice Guideline Recommendation Classification System A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice
More informationUpdated Guidelines for Management of Candidiasis. Vidya Sankar, DMD, MHS April 6, 2017
Updated Guidelines for Management of Candidiasis Vidya Sankar, DMD, MHS April 6, 2017 Statement of Disclosure I have no actual or potential conflict of interest in relation to this presentation Outline
More informationSystemic Candidiasis for the clinicians: between guidelines and daily clinical practice
Systemic Candidiasis for the clinicians: between guidelines and daily clinical practice Anastasia Antoniadou Assoc. Professor Internal Medicine and Infectious Diseases National and Kapodistrian University
More informationIMPLEMENTING RECOVERY ORIENTED CLINICAL SERVICES IN OPIOID TREATMENT PROGRAMS PILOT UPDATE. A Clinical Quality Improvement Program
IMPLEMENTING RECOVERY ORIENTED CLINICAL SERVICES IN OPIOID TREATMENT PROGRAMS PILOT UPDATE A Clinical Quality Improvement Program Today: National completion rates for OTP s hover between 11 14% Retention
More informationInfectious Disease in the Critically Ill Patient
Infectious Disease in the Critically Ill Patient Heather L. Evans, MD MS FACS Director of Surgical Infectious Disease Harborview Medical Center Asst. Professor UW Department of Surgery New Antibiotics:
More informationLarge trials vs observational studies in assessing benefit and harm: the example of aprotinin
Large trials vs observational studies in assessing benefit and harm: the example of aprotinin Dean A. Fergusson, MHA, PhD Senior Scientist and Associate Director, Clinical Epidemiology Program, Ottawa
More informationUnderstanding the Role of Palliative Care in the Treatment of Cancer Patients
Understanding the Role of Palliative Care in the Treatment of Cancer Patients Palliative care is derived from the Latin word palliare, to cloak. This is a form of medical care or treatment that concentrates
More informationCURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS. Dr AMIT RAODEO DM SEMINAR
CURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS Dr AMIT RAODEO DM SEMINAR Introduction The incidence of invasive fungal infections in critically ill intensive
More information7 Quantitative Health Sciences and 8 Infectious
LIVER TRANSPLANTATION 18:1100-1109, 2012 ORIGINAL ARTICLE Invasive Fungal Infections Following Liver Transplantation: Incidence, Risk Factors, Survival, and Impact of Fluconazole-Resistant Candida parapsilosis
More informationFungal Infection Pre-Infusion Data
Fungal Infection Pre-Infusion Data Registry Use Only Sequence Number: Date Received: CIBMTR Center Number: Event date: / / CIBMTR Form 2046 revision 5 (page 1 of 5). Last Updated May, 2018. Infection Episode
More informationCandidemia: New Sentinel Surveillance in the 7-County Metro
Candidemia: New Sentinel Surveillance in the 7-County Metro Brittany VonBank, MPH Paula Vagnone, MT (ASCP) 651-201-5414 www.health.state.mn.us Health Care-associated Infections & Antimicrobial Resistance
More informationMed Wreck to Med Rec How medication reconciliation can (should) change your practice!
Med Wreck to Med Rec How medication reconciliation can (should) change your practice! Dan Martinusen BSc(Pharm),ACPR, PharmD Chair, BCPRA Pharmacy & Formulary Committee Marianna Leung B Sc(Pharm), ACPR,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Vfend) Reference Number: AZ.CP.PHAR.39 Effective Date: 11.16.16 Last Review Date: 09.11.18 Line of Business: Arizona Medicaid Revision Log See Important Reminder at the end of this policy
More informationINFEZIONI FUNGINE E PERCORSI TERAPEUTICI IN ICU. Claudio Viscoli Professor of Infectious Disease University of Genoa
INFEZIONI FUNGINE E PERCORSI TERAPEUTICI IN ICU Claudio Viscoli Professor of Infectious Disease University of Genoa What I would like to discuss with you today When to start an antifungal therapy (before
More informationMedication Policy Manual. Topic: Juxtapid, lomitapide Date of Origin: May 16, 2013
Medication Policy Manual Policy No: dru302 Topic: Juxtapid, lomitapide Date of Origin: May 16, 2013 Committee Approval Date: March 13, 2015 Next Review Date: March 2016 Effective Date: April 1, 2015 IMPORTANT
More informationTerapia della candidiasi addomaniale
Verona 16 marzo 2018 Terapia della candidiasi addomaniale Pierluigi Viale Infectious Disease Unit Teaching Hospital S. Orsola Malpighi Bologna INTRA ABDOMINAL CANDIDIASIS open questions a single definition
More informationEpidemiology of Invasive Mold Infections in Lung Transplant Recipients
American Journal of Transplantation 2014; 14: 1328 1333 Wiley Periodicals Inc. C Copyright 2014 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/ajt.12691
More informationClinical Policy: Itraconazole (Onmel, Sporanox) Reference Number: ERX.NPA.25 Effective Date:
Clinical Policy: (Onmel, Sporanox) Reference Number: ERX.NPA.25 Effective Date: 06.01.15 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and
More informationImproving Influenza Vaccination Rates in Critical Access Hospitals 10/26/2016
Improving Influenza Vaccination Rates in Critical Access Hospitals 10/26/2016 Objectives Provide an overview of OP 27 Influenza Vaccination Among Healthcare Personnel (HCP) and IMM 2 Immunization for influenza
More informationReducing Falls Causing Harm in Older People with Dementia. Professor Tony Elliott South Staffordshire and Shropshire FT
Reducing Falls Causing Harm in Older People with Dementia Professor Tony Elliott South Staffordshire and Shropshire FT Project Site 16 bedded Dementia Inpatient Unit Acute admissions from home, DGHs or
More informationArmed Services Blood Program
Armed Services Blood Program Defense Health Board Concerns Regarding the Collection and Transfusion of Non-FDA Compliant Blood Products in Theater Information Brief Defense Health Board 17 August 2009
More information9/7/2018. Faculty. Overcoming Challenges in the Management of Invasive Fungal Infections. Learning Objectives. Faculty Disclosure
Faculty Overcoming Challenges in the Management of Invasive Fungal James S. Lewis II, PharmD, FIDSA ID Clinical Pharmacy Coordinator Oregon Health and Science University Departments of Pharmacy and Infectious
More informationMANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS
MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS Paul D. Holtom, MD Associate Professor of Medicine and Orthopaedics USC Keck School of Medicine Numbers of Cases of Sepsis in the United States, According
More information